Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations

[1]  M. Pellegrini,et al.  Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts , 2022, Blood cancer discovery.

[2]  Y. Natkunam,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms , 2022, Leukemia.

[3]  H. Kantarjian,et al.  Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes , 2021, Cancer.

[4]  T. Druley,et al.  The evolutionary dynamics and fitness landscape of clonal hematopoiesis , 2020, Science.

[5]  K. Pradhan,et al.  U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies , 2019, Nature Cell Biology.

[6]  K. Götze,et al.  A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS , 2018, Leukemia.

[7]  H. Deeg,et al.  SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. , 2015, Cancer cell.

[8]  S. Miyano,et al.  Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome , 2014, Nature Communications.

[9]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[10]  C Haferlach,et al.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.

[11]  M. Stratton,et al.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[12]  M. Cazzola,et al.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.

[13]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[14]  Y. Nagata.  [Molecular international prognostic scoring system for myelodysplastic syndromes]. , 2023, [Rinsho ketsueki] The Japanese journal of clinical hematology.